🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors

RecruitingNAAges 18 Years - 85 YearsAllRoberto Valente
NCT07191418 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer and may become the second leading cause of cancer death by 2030. About half of the patients are diagnosed late, when the cancer has already spread (mPDAC), and the outlook is very poor. Chemotherapy is currently the only treatment for mPDAC. It can slow the disease and slightly extend life, but usually only by a few months. There are no other treatments that clearly improve survival. Radiofrequency ablation (RFA) is a minimally invasive technique that uses high-frequency electrical energy to generate heat and destroy tumor cells. Radiofrequency energy raises the temperature of the tissue, leading to coagulative necrosis and tumor cell death. RFA is commonly used to treat certain types of cancer and pre-cancerous lesions, including liver, kidney, lung, and bone tumors. In addition to directly destroying tumor tissue, RFA

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Individuals with newly diagnosed pancreatic cancer in the head of the pancreas causing compression on the bile duct. * Metastatic stage to the liver * Histologically or cytologically confirmed mPDAC. * Cancer burden limited to maximum 5 metastases in the liver, each of them maximum 1 cm in the larger diameter. * Patients must be under palliative chemotherapy treatment. * Cancer should be radiologically measurable (in an area not previously irradiated). * WHO performance status 0-2. * Age 18-85 years. Exclusion Criteria: * Intellectual disability, unwillingness or language difficulties * which hinders the ability to give informed consent. * Ongoing extensive immunosuppression and/or severe leuko- or * thrombocytopenia. * Ongoing acute cholangitis. * Ongoing sepsis. * Acute kidney failure. * Uncompensated heart failure or unstable coronary insufficiency * (symptomatic/uncompensated). * Pregnancy or breastfeeding. * Any metastases outside the liver. * Cardiac pacemakers/cardioverter defibrillators. * Severe coagulopathy.
💊

What it tests

  • Habib™ EndoHPB
  • ERCP
📍

Where

1 site
Department of Surgery, Umeå University Hospital
Umeå, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy